Pyxis Oncology, Inc. (PYXS): Price and Financial Metrics
GET POWR RATINGS... FREE!
PYXS Stock Price Chart Interactive Chart >
PYXS Price/Volume Stats
| Current price | $1.59 | 52-week high | $9.87 |
| Prev. close | $1.60 | 52-week low | $1.10 |
| Day low | $1.59 | Volume | 10,316 |
| Day high | $1.65 | Avg. volume | 39,961 |
| 50-day MA | $1.38 | Dividend yield | N/A |
| 200-day MA | $2.14 | Market Cap | 55.80M |
Pyxis Oncology, Inc. (PYXS) Company Bio
Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Latest PYXS News From Around the Web
Below are the latest news stories about PYXIS ONCOLOGY INC that investors may wish to consider to help them evaluate PYXS as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayThe biggest pre-market stock movers for Monday include many Chinese shares that traders will want to keep an eye on today! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning! |
How is PYXS’s stock performing after recent trades?In the current trading session, Pyxis Oncology Inc.’s (PYXS) stock is trading at the price of $1.48, a gain of 2.07% over last night’s close. So, the stock is trading at a price that is -88.56% less than its 52-week high of $12.94 and 10.45% better than its 52-week low of $1.34. Based on the […] |
CTXR, SCYX and TOPS are among pre market gainersRa Medical Systems (RMED) +22%. Okta (OKTA) +17% Q3earnings call releasePyxis Oncology (PYXS) +14% gains on FDA nod to start two Phase 1 trials for cancer drugs.SOBR Safe… |
PYXS stock gains on FDA nod to start two Phase 1 trials for cancer drugs (NASDAQ:PYXS)Development-stage biotech Pyxis Oncology (PYXS) announced Thursday that the FDA cleared two of its Investigational New Drug ((IND)) applications permitting the company to start Phase… |
PYXS Price Returns
| 1-mo | 26.19% |
| 3-mo | -15.43% |
| 6-mo | -40.00% |
| 1-year | -81.32% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 18.66% |
| 2022 | -87.78% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...